AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:26:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Firing on All Cylinders: CONMED (NYSE:CNMD) Q1 Earnings Lead the Way
Tue 20 May 25, 03:35 AMTop Stock Movers Now: UnitedHealth Group, Walmart, Deere, and More
Thu 15 May 25, 03:58 PMSTE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
Thu 15 May 25, 12:40 PMHere's What Key Metrics Tell Us About Steris (STE) Q4 Earnings
Wed 14 May 25, 10:30 PMSteris (STE) Surpasses Q4 Earnings Estimates
Wed 14 May 25, 09:45 PMSTERIS’s (NYSE:STE) Q1 Earnings Results: Revenue In Line With Expectations
Wed 14 May 25, 08:41 PMSTERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
Wed 14 May 25, 08:30 PMNuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates
Tue 13 May 25, 12:15 PMSTERIS (STE) Q1 Earnings: What To Expect
Tue 13 May 25, 07:01 AM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 157.35M | 314.50M | 517.53M | 498.68M | 369.47M |
| Minority interest | 1.22M | 1.02M | -0.53000M | 12.85M | 7.99M |
| Net income | 107.03M | 243.89M | 397.40M | 407.61M | 304.05M |
| Selling general administrative | 1298.88M | 1502.75M | 731.32M | 717.53M | 653.97M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2159.69M | 2016.36M | 1343.10M | 1319.92M | 1175.43M |
| Reconciled depreciation | 552.90M | 553.10M | 219.24M | 197.24M | 225.92M |
| Ebit | 268.19M | -127.39000M | 323.30M | 341.08M | 247.52M |
| Ebitda | 1250.29M | 425.71M | 542.54M | 538.32M | 473.44M |
| Depreciation and amortization | 982.10M | 553.10M | 219.24M | 197.24M | 225.92M |
| Non operating income net other | -2.84800M | - | 6.34M | 1.99M | 3.02M |
| Operating income | 268.19M | 425.62M | 323.30M | 341.08M | 411.46M |
| Other operating expenses | 4198.60M | 4159.40M | 2562.07M | 2493.25M | 2339.72M |
| Interest expense | 109.62M | 89.59M | 37.18M | 40.28M | 45.02M |
| Tax provision | 51.53M | 71.63M | 120.66M | 90.88M | 64.39M |
| Interest income | 110.84M | 6.28M | 6.34M | 38.29M | 41.99M |
| Net interest income | -110.83700M | -83.30900M | -30.83500M | -38.29200M | -41.99500M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 491.05M | - | -2.91400M | 0.67M | 30.99M |
| Other items | - | - | - | - | - |
| Income tax expense | 51.53M | 71.63M | 120.66M | 90.88M | 64.39M |
| Total revenue | 4957.84M | 4585.06M | 3107.52M | 3030.89M | 2782.17M |
| Total operating expenses | 1400.46M | 1590.70M | 797.65M | 782.28M | 732.98M |
| Cost of revenue | 2798.15M | 2568.70M | 1764.42M | 1710.97M | 1606.74M |
| Total other income expense net | -601.88700M | -111.16300M | -27.92100M | -38.96500M | -72.98200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 105.81M | 242.87M | 396.87M | 407.81M | 305.08M |
| Net income applicable to common shares | 107.03M | 243.89M | 397.40M | 407.61M | 303.72M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 10821.84M | 11452.60M | 6574.47M | 5425.58M | 5073.07M |
| Intangible assets | 2955.78M | 3328.54M | 898.41M | 565.47M | 604.61M |
| Earning assets | - | - | - | - | - |
| Other current assets | 179.28M | 156.64M | 66.75M | 54.43M | 60.03M |
| Total liab | 4734.67M | 4907.96M | 2683.00M | 2018.86M | 1887.27M |
| Total stockholder equity | 6087.17M | 6544.64M | 3891.47M | 3406.72M | 3185.80M |
| Deferred long term liab | 617.54M | - | 236.86M | 160.27M | 151.04M |
| Other current liab | 394.98M | 406.35M | 335.70M | 281.16M | 312.28M |
| Common stock | 4486.38M | 4742.92M | 2002.83M | 1982.16M | 1998.56M |
| Capital stock | 4486.38M | 4742.92M | 2002.83M | 1982.16M | 1998.56M |
| Retained earnings | 1911.53M | 1999.24M | 1939.41M | 1647.17M | 1339.02M |
| Other liab | 693.67M | 1040.26M | 454.54M | 250.62M | 238.85M |
| Good will | 3879.22M | 4404.34M | 3026.05M | 2356.09M | 2322.93M |
| Other assets | 78.14M | 70.66M | 52.72M | 51.58M | 60.21M |
| Cash | 208.36M | 348.32M | 220.53M | 319.58M | 220.63M |
| Cash and equivalents | 208.36M | 348.32M | 220.53M | 319.58M | 220.63M |
| Total current liabilities | 861.84M | 922.22M | 577.92M | 503.61M | 465.20M |
| Current deferred revenue | 92.28M | 110.79M | 62.49M | 53.30M | 55.33M |
| Net debt | 2810.30M | 2776.51M | 1430.01M | 830.94M | 962.59M |
| Short term debt | 94.96M | 179.35M | 22.77M | 19.81M | -55.33300M |
| Short long term debt | 60.00M | 142.88M | - | - | - |
| Short long term debt total | 3018.66M | 3124.83M | 1650.54M | 1150.52M | 1183.23M |
| Other stockholder equity | 9.97M | 12.28M | 10.48M | 12.85M | 7.99M |
| Property plant equipment | 1705.51M | 1741.06M | 1235.40M | 1243.69M | 1031.58M |
| Total current assets | 2011.44M | 1879.00M | 1211.75M | 1208.75M | 1053.73M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 2197.98M | -1217.24800M | 854.94M | 472.32M | 250.27M |
| Short term investments | - | - | - | - | - |
| Net receivables | 928.32M | 799.04M | 609.41M | 586.48M | 564.83M |
| Long term debt | 3018.66M | 2945.48M | 1650.54M | 1150.52M | 1183.23M |
| Inventory | 695.49M | 575.00M | 315.07M | 248.26M | 208.24M |
| Accounts payable | 279.62M | 225.74M | 156.95M | 149.34M | 152.91M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 9.97M | - | 10.48M | 12.85M | 7.99M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -320.71000M | -209.80800M | -61.24300M | -235.46300M | -159.77800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 4486.38M | - | 2002.83M | 1982.16M | 1998.56M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 1911.53M | - | 1939.41M | 1647.17M | 1339.02M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 78.14M | 70.66M | 52.72M | 51.58M | 60.21M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 8810.40M | 9573.60M | 5362.72M | 4216.83M | 4019.34M |
| Capital lease obligations | 195.45M | 191.53M | 152.45M | 133.92M | 0.00000M |
| Long term debt total | 3018.66M | 2945.48M | 1650.54M | 1150.52M | 1183.23M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -383.33000M | -666.55900M | -4.40000M | -319.73500M | -4.95500M |
| Change to liabilities | 31.29M | 14.89M | 2.70M | 3.41M | 80.37M |
| Total cashflows from investing activities | -383.33000M | -666.55900M | -1154.15900M | -319.73500M | -213.22400M |
| Net borrowings | 150.66M | 372.18M | 471.69M | -27.78100M | -112.57500M |
| Total cash from financing activities | -498.71800M | 115.83M | 345.62M | -163.14600M | -294.79200M |
| Change to operating activities | -46.14000M | -148.82000M | 19.01M | 9.97M | 51.76M |
| Net income | 105.81M | 242.87M | 396.87M | 407.81M | 305.08M |
| Change in cash | -139.96300M | 127.79M | -99.05000M | 98.95M | 19.10M |
| Begin period cash flow | 348.32M | 220.53M | 319.58M | 220.63M | 201.53M |
| End period cash flow | 208.36M | 348.32M | 220.53M | 319.58M | 220.63M |
| Total cash from operating activities | 756.95M | 684.81M | 689.64M | 590.56M | 539.50M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 552.90M | 553.10M | -30.20600M | -33.23400M | 225.92M |
| Other cashflows from investing activities | -21.36100M | -378.99600M | -910.49700M | -105.21900M | -18.55400M |
| Dividends paid | -183.49800M | -163.16900M | -133.83700M | -123.03400M | 112.50M |
| Change to inventory | -123.92100M | -102.92200M | 3.77M | -39.06700M | -14.17600M |
| Change to account receivables | -133.30400M | -51.96900M | 12.08M | -17.86600M | -48.48600M |
| Sale purchase of stock | -308.56500M | -55.77700M | -14.64600M | -51.24100M | -81.49400M |
| Other cashflows from financing activities | -2.26500M | 1962.60M | -17.16200M | 2.90M | -1.81500M |
| Change to netincome | 340.90M | 223.31M | 54.53M | 35.26M | -1.38900M |
| Capital expenditures | 361.97M | 287.56M | 239.26M | 214.52M | 189.72M |
| Change receivables | -133.30400M | - | 12.08M | -17.86600M | -48.48600M |
| Cash flows other operating | -16.72300M | - | 0.46M | 3.78M | -7.37100M |
| Exchange rate changes | - | - | 19.85M | -8.73000M | -12.39000M |
| Cash and cash equivalents changes | -125.10100M | - | -99.05000M | 98.95M | 19.10M |
| Change in working capital | -250.02300M | -148.82000M | 19.01M | -49.73700M | 9.90M |
| Stock based compensation | 38.95M | 57.66M | 25.97M | 23.81M | 23.96M |
| Other non cash items | 495.22M | 86.62M | 273.76M | 232.49M | -18.73200M |
| Free cash flow | 394.98M | 397.25M | 450.38M | 376.04M | 349.79M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| STE STERIS plc |
-5.64 2.48% | 222.08 | 39.82 | 23.26 | 4.06 | 3.44 | 4.72 | 18.08 |
| ABT Abbott Laboratories |
-2.1 1.86% | 110.55 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-7.27 1.99% | 358.65 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-1.45 1.59% | 89.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-1.94 2.70% | 69.96 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
70 Sir John Rogerson?s Quay, Dublin, Ireland, D02 R296
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel A. Carestio | Pres, CEO & Director | 1973 |
| Mr. Michael J. Tokich | Sr. VP & CFO | 1969 |
| Mr. John Adam Zangerle | Sr. VP, Gen. Counsel & Sec. | 1967 |
| Mr. Walter M. Rosebrough Jr. | CEO Emeritus & Sr. Advisor | 1954 |
| Mr. Cary L. Majors | Sr. VP of Americas Commercial Operations | 1975 |
| Mr. Andrew Xilas | Sr. VP & GM of Dental | 1965 |
| Ms. Karen L. Burton | Chief Accounting Officer, VP & Controller | 1968 |
| Julie Winter | VP of Investor Relations & Corp. Communications | NA |
| Ms. Mary Clare Fraser | VP & Chief HR Officer | 1970 |
| Ms. Julia K. Madsen | Sr. VP of Life Sciences | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...